Click’s CT-132 has been designed for reducing the number of migraines that occur per month. Credit: Usman Yousaf on Unsplash.

Click Therapeutics has secured Breakthrough Device Designation for its CT-132 prescription digital therapeutic to treat episodic migraine, from the US Food and Drug Administration (FDA).

CT-132 is currently under development as an adjunctive preventive treatment for episodic migraine in people of age 18 years and above.

Go deeper with GlobalData

Go deeper with GlobalData

The gold standard of business intelligence.

Find out more

Discover B2B Marketing That Performs

Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.

Find out more

It has been designed for reducing the number of migraines that occur per month in patients suffering with four or more migraine days per month.

CT-132 combines the company’s adaptive patient engagement platform with multiple clinically validated mechanisms of action.

Click Therapeutics chief strategy officer Austin Speier said: “We are thrilled to receive this Breakthrough designation as it will facilitate collaborative discussions with the FDA and help expedite the process of bringing a first-in-class migraine digital therapeutic to patients.

“This is also powerful recognition of the innovative work led by our in-house science and development teams to create a new approach to treating migraine, one supported by early, promising clinical data.”

GlobalData Strategic Intelligence

US Tariffs are shifting - will you react or anticipate?

Don’t let policy changes catch you off guard. Stay proactive with real-time data and expert analysis.

By GlobalData

The company stated that the CT-132 programme is authorised by the active support of its Migraine Advisory Board.

Using and extending its patented Click Neurobehavioral Intervention (CNI) Platform, Click has finished or started three clinical trials on CT-132.

Upon completion, the data will support the product’s regulatory submission to the FDA.

Click Therapeutics chief medical officer Shaheen Lakhan said: “Breakthrough further affirms that our unique approach to unlock undruggable CNS targets has merit through the combination of digital neuroactivation and modulation (DiNaMo) and neurobehavioral interventions.

“Through this new paradigm, we aim to restore lives ravaged by debilitating brain diseases like migraine.”

The company develops, validates, and commercialises software as prescription medical treatments for people suffering with unmet medical requirements.

Medical Device Network Excellence Awards - Nominations Closed

Nominations are now closed for the Medical Device Network Excellence Awards. A big thanks to all the organisations that entered – your response has been outstanding, showcasing exceptional innovation, leadership, and impact

Excellence in Action
HemoSonics has won the 2025 Marketing Award for its impactful promotion of theQuantra Hemostasis System and leadership in blood management education. See how targeted campaigns, thought leadership content, and hands on clinician training are accelerating Quantra’s market traction and shaping the future of hemostasis testing.

Discover the Impact